OBJECTIVE: The multiple organ dysfunction syndrome (MODS) is the sequential failure of several organ systems after a trigger event, such as sepsis, pneumonia or cardiogenic shock. Even today, mortality is high. Statin therapy is associated with reduction of inflammation and subsequent rates of severe sepsis and ICU admission of patients admitted to hospital with presumed or documented acute bacterial infection. Our study aimed to characterize a potential survival benefit by statin therapy in MODS patients. DESIGN: Retrospective cohort study. SETTING: Twelve-bed medical intensive care unit in a university center. PATIENTS: Forty score-defined MODS patients under statin treatment and 80 age- and sex-matched score-defined MODS patients without statin treatment. Inclusion criterion was an APACHE II score > or = 20 at admission to ICU. INTERVENTIONS: Assessment of statin treatment and calculation of disease severity by scoring. The patients were followed up for 28-day mortality as well as for hospital mortality. MEASUREMENTS AND RESULTS: The MODS severity was equally pronounced in both groups. There were 42/80 deaths in the group without statin treatment and 13/40 deaths in the statin group (28-day mortality 53% vs. 33%, p = 0.03). Cox proportional hazard analysis revealed a hazard ratio of 0.53 (95% CI 0.29-0.99, p = 0.04). Hospital mortality was calculated at 72% (non-statin group) vs. 35% (statin group; chi-square = 15.6, p < 0.0001). The overall hospital mortality was 60%. CONCLUSIONS: Patients under statin treatment developing MODS might have a better outcome than patients without statin therapy, probably by reduction of inflammatory responses and increase of vagal activity in MODS.
OBJECTIVE: The multiple organ dysfunction syndrome (MODS) is the sequential failure of several organ systems after a trigger event, such as sepsis, pneumonia or cardiogenic shock. Even today, mortality is high. Statin therapy is associated with reduction of inflammation and subsequent rates of severe sepsis and ICU admission of patients admitted to hospital with presumed or documented acute bacterial infection. Our study aimed to characterize a potential survival benefit by statin therapy in MODS patients. DESIGN: Retrospective cohort study. SETTING: Twelve-bed medical intensive care unit in a university center. PATIENTS: Forty score-defined MODS patients under statin treatment and 80 age- and sex-matched score-defined MODS patients without statin treatment. Inclusion criterion was an APACHE II score > or = 20 at admission to ICU. INTERVENTIONS: Assessment of statin treatment and calculation of disease severity by scoring. The patients were followed up for 28-day mortality as well as for hospital mortality. MEASUREMENTS AND RESULTS: The MODS severity was equally pronounced in both groups. There were 42/80 deaths in the group without statin treatment and 13/40 deaths in the statin group (28-day mortality 53% vs. 33%, p = 0.03). Cox proportional hazard analysis revealed a hazard ratio of 0.53 (95% CI 0.29-0.99, p = 0.04). Hospital mortality was calculated at 72% (non-statin group) vs. 35% (statin group; chi-square = 15.6, p < 0.0001). The overall hospital mortality was 60%. CONCLUSIONS:Patients under statin treatment developing MODS might have a better outcome than patients without statin therapy, probably by reduction of inflammatory responses and increase of vagal activity in MODS.
Authors: Hendrik Schmidt; Ursula Müller-Werdan; Thomas Hoffmann; Darrel P Francis; Massimo F Piepoli; Mathias Rauchhaus; Roland Prondzinsky; Harald Loppnow; Michael Buerke; Dirk Hoyer; Karl Werdan Journal: Crit Care Med Date: 2005-09 Impact factor: 7.598
Authors: Sabine Steiner; Walter S Speidl; Johannes Pleiner; Daniela Seidinger; Gerlinde Zorn; Christoph Kaun; Johann Wojta; Kurt Huber; Erich Minar; Michael Wolzt; Christoph W Kopp Journal: Circulation Date: 2005-04-12 Impact factor: 29.690
Authors: Marc W Merx; Elisa A Liehn; Uwe Janssens; Rudolf Lütticken; Jürgen Schrader; Peter Hanrath; Christian Weber Journal: Circulation Date: 2004-05-03 Impact factor: 29.690
Authors: Weiguo Chen; Rajesh Sharma; Alicia N Rizzo; Jessica H Siegler; Joe G N Garcia; Jeffrey R Jacobson Journal: Am J Respir Cell Mol Biol Date: 2014-02 Impact factor: 6.914
Authors: Ciaran Skerry; Michael L Pinn; Natalie Bruiners; Richard Pine; Maria L Gennaro; Petros C Karakousis Journal: J Antimicrob Chemother Date: 2014-05-22 Impact factor: 5.790
Authors: Kelly Lima Calisto; Bruno de Melo Carvalho; Eduardo Rochete Ropelle; Francine Cappa Mittestainer; Angélica Costa Aranha Camacho; Dioze Guadagnini; José Barreto Campelo Carvalheira; Mario José Abdalla Saad Journal: PLoS One Date: 2010-12-06 Impact factor: 3.240
Authors: Holger C Müller; Katharina Hellwig; Simone Rosseau; Thomas Tschernig; Andreas Schmiedl; Birgitt Gutbier; Bernd Schmeck; Stefan Hippenstiel; Harm Peters; Lars Morawietz; Norbert Suttorp; Martin Witzenrath Journal: Crit Care Date: 2010-07-30 Impact factor: 9.097
Authors: Steffen Christensen; Reimar W Thomsen; Martin B Johansen; Lars Pedersen; Reinhold Jensen; Kim M Larsen; Anders Larsson; Else Tønnesen; Henrik Toft Sørensen Journal: Crit Care Date: 2010-03-09 Impact factor: 9.097